


## PHARMACEUTICAL 2021

## Acer Therapeutics Inc. Rank 378 of 409







## PHARMACEUTICAL 2021

## Acer Therapeutics Inc. Rank 378 of 409



The relative strengths and weaknesses of Acer Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acer Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 387% points. The greatest weakness of Acer Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 462% points.

The company's Economic Capital Ratio, given in the ranking table, is -799%, being 444% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	6,441
Cost of Goods Sold	0
Intangible Assets	7,647
Liabilities, Current	6,146
Liabilities, Non-Current	244
Other Assets	395
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-83
Property and Equipment	130
Research and Development	11,848
Revenues	0
Selling, General and Administrative Expense	10,955

Output Variable	Value in 1000 USD
Assets	14,614
Liabilities	6,389
Expenses	22,803
Stockholders Equity	8,224
Net Income	-22,885
Comprehensive Net Income	-22,885
Economic Capital Ratio	-799%